Depemokimab (2) – Exdensur®
Chronic rhinosinusitis with nasal polyps
Characteristics
| Start date | 01.04.2026 |
|---|---|
| Resolution | 01.10.2026 – active procedure |
| INN | Depemokimab |
| Brand name | Exdensur® |
| Pharm. company | GlaxoSmithKline GmbH & Co. KG |
| G-BA Procedure ID | D-1311 |
| Therapeutic area | Respiratory system diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions